Home › Companies › AUTL

Autolus Therapeutics

Market cap $290M 266.3M shares (10-Q, Nov 9, 2026) × $1.09 close Nov 17, 2026

Most recent annual filing: 2026-03-27

Catalyst timeline

10 trackedQuarter catalyst calendar →
  1. CARLYSLE SLE Ph1 interimYear-end 2026CARLYSLE SLE Ph1 interim, Year-end 2026, notable
  2. ALARIC AL Ph1 interimYear-end 2026ALARIC AL Ph1 interim, Year-end 2026, notable
  3. AUTO1/22 CARPALL readoutlate 2026AUTO1/22 CARPALL readout, late 2026, notable
  4. AUTO8 readoutDec 12, 2026AUTO8 readout, Dec 12, 2026, notable
  5. Perceptive Note Facility manufacturing updateJan 30, 2027Perceptive Note Facility manufacturing update, Jan 30, 2027, routine
  6. CATULUS Pediatric r Ph2 toplineYear-end 2027CATULUS Pediatric r Ph2 topline, Year-end 2027, material
  7. BOBCAT MS Ph1 interimOct 2027BOBCAT MS Ph1 interim, Oct 2027, major
  8. BOBCAT MS Ph2 readoutOct 2027BOBCAT MS Ph2 readout, Oct 2027, material
  9. Company cash runway corporate update4Q 2027Company cash runway corporate update, 4Q 2027, routine
  10. LUMINA LN Ph2 topline2028LUMINA LN Ph2 topline, 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Capital (as filed)

Cash
$245M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$3.0M Sep 30, 2026
Operating cash flow
−$18.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$248M cash, runway Q2 2028 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Autolus Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Autolus Therapeutics (AUTL) — Scientific Deep Dive for Obe-cel and Pipeline Products Real revenue and differentiated biology exist, but the royalty stack and likely 2027 dilution event prevent a clean BUY; upgrade triggers are Q2/Q3 revenue tracking to high end of guidance or a clean BOBCAT Phase 1 biomarker readout.
  2. Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - The Dilution Gap Just Got Debt-Financed Condition (a) from the May writeup has been met — Q2 revenue accelerated ~70% sequentially, guidance raised above the old high end, and the dilution gap was bridged with debt at ~1.3% warrant dilution rather than a punishing equity print, extending runway into Q2 2028.
  3. Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - 55% Gross Margin, and the MS Catalyst Just Slid a Quarter Q2 gross margin printed at 55% (better than the blended 35% pre-announced), confirming the commercial thesis, but BOBCAT MS readout slipped to Q1 2027 and the stock has already run +28%, so no upgrade to clean BUY is warranted.
  4. Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - The FDA Just Blessed the n=6 FDA RMAT designation in SLE/LN directly addresses the bear-case risk of the agency not accepting a single-arm registrational path, but the designation is procedural rather than data and no upgrade to clean BUY is warranted ahead of the November covenant test and Q4 clinical prints.
  5. Speculative buy speculative UPDATE: Autolus Therapeutics (AUTL) - The Lupus Data Got Better, the Revenue Line Blinked CARLYSLE lupus data improved (6/9 CRR, DORIS in all patients followed 6+ months, clean safety at n=15) but Q3 revenue declined ~10% sequentially for the first time since launch and BOBCAT slipped again to October 2027, making Q4 revenue the key decision point for maintaining the upgrade.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

17 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)